Abcuro has commenced a registrational Phase ll/lll trial of ABC008 for the treatment of inclusion body myositis (IBM).
ABC008 is an anti-KLRG1 antibody that has been designed to selectively reduce highly cytotoxic T cells without harming regulatory and central memory T cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
IBM is an autoimmune disease where highly cytotoxic T cells continuously attack muscle tissue, thereby causing patients to gradually lose muscle function, such as loss of grip, dexterity and mobility.
In a Phase l study, Abcuro observed potent, durable, and dose-dependent reduction of CD8+KLRG1+ T cells, the most highly cytotoxic T cells.
The dose levels of the Phase ll/lll study showed 97% depletion of blood target cells at 28 days after injection.
This trial will include over 200 patients across 30 sites worldwide.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe randomised, double-blind, placebo-controlled, parallel multicentre trial will be carried out in three phases.
Abcuro chief medical officer Jeffrey Wilkins said: “This registrational Phase ll/lll trial represents an important milestone for patients with IBM.
“It builds upon the compelling proof of mechanism observed with ABC008 to potently and selectively deplete highly cytotoxic T cells which attack and destroy muscle tissue in IBM, without affecting protective T cell populations.
“This approach differentiates ABC008 from broad T cell depleters whose use has been limited by adverse effects associated with broad immune-cell depletion.”
